Deals in Depth: October 2010
Executive Summary
Teaming up for the sixth time, Exelixis penned a $545 million deal with BMS for early-stage type 2 diabetes and inflammation candidates. Stryker/Boston Scientific's neurovascular business and St. Jude/AGA Medical were the two billion-dollar acquisitions in devices. Biopharma financing hugely increased to over $2 billion in October. Device fundraising reached $280 million, almost exactly as much as September's total.